Sergio A. Giralt, MD

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.

Sergio A. Giralt, MD, discusses the rationale for investigating idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.

Sergio A. Giralt, MD, discusses the results of a phase 3 trial comparing omidubicel with standard umbilical cord blood transplant in hematologic malignancies.

Sergio A. Giralt, MD, discusses the current frontline standard of care for patients with multiple myeloma.

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses methods of evaluating measurable residual disease (MRD) in multiple myeloma.

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.